English Roberts
Primary Care · Decatur, TNNPI 1326384991
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 235 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations.
Across 235 payments — averaging $16.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$849
- Novo Nordisk$437
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$362
- AstraZeneca$279
- Otsuka America Pharmaceutical, Inc.$238
- Silk Road Medical, Inc.$189
- plus $1K from 31 others
What the payments were for
- Food & beverage$3,848100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 61 | $849 |
| Novo Nordisk | 28 | $437 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $362 |
| AstraZeneca | 19 | $279 |
| Otsuka America Pharmaceutical, Inc. | 13 | $238 |
| Silk Road Medical, Inc. | 2 | $189 |
| Lilly USA, LLC | 11 | $181 |
| Amgen | 15 | $178 |
| Boehringer Ingelheim | 7 | $110 |
| Lundbeck LLC | 4 | $107 |
| Boston Scientific | 1 | $72 |
| Phathom Pharmaceuticals, Inc. | 4 | $68 |
| Axsome Therapeutics, Inc. | 3 | $66 |
| Pfizer | 4 | $62 |
| Novartis | 4 | $61 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $57 |
| Intra-sana Laboratories | 4 | $56 |
| Biodelivery Sciences International, Inc. | 4 | $51 |
| Gilead | 2 | $48 |
| Mycovia Pharmaceuticals, Inc. | 2 | $35 |
| Paratek Pharmaceuticals, Inc. | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| GSK | 2 | $31 |
| Cycle Pharmaceuticals Inc | 1 | $26 |
| Merck | 1 | $22 |
| Insulet Corporation | 1 | $22 |
| Antares Pharma, Inc. | 1 | $21 |
| Medtronic | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Bayer | 1 | $16 |
| Scynexis, Inc. | 1 | $15 |
| Abbott | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
How this compares
$3,848 in reported general payments places this provider in the 85th percentile of 189 primary care providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 104 | $87,415 |
| EliquisApixaban | 58 | $43,640 |
| MounjaroTirzepatide | 36 | $39,027 |
| RexultiBrexpiprazole | 22 | $31,462 |
| TrulicityDulaglutide | 29 | $28,980 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $25,732 |
| OzempicSemaglutide | 25 | $23,478 |
| FarxigaDapagliflozin Propanediol | 22 | $16,150 |
| Repatha SureclickEvolocumab | 20 | $15,101 |
| Novolog FlexpenInsulin Aspart | 40 | $12,202 |
| Nurtec OdtRimegepant Sulfate | 11 | $11,780 |
| MyrbetriqMirabegron | 19 | $10,974 |
| LinzessLinaclotide | 20 | $10,712 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,898 |
| TrintellixVortioxetine Hydrobromide | 12 | $6,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $110 | $87,415104 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $181 | $69,92391 claims |
| PfizerEliquis, Nurtec Odt | $62 | $55,42169 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $238 | $31,46222 claims |
| GSKTrelegy Ellipta | $31 | $25,73237 claims |
| Novo NordiskOzempic | $437 | $23,47825 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $279 | $23,04833 claims |
| AbbVieLinzess | $849 | $10,71220 claims |
| Sanofi-aventis U.S. LLCLantus | $12 | $1,46823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 189 primary care providers in Tennessee.
Other primary care in Decatur
- Jamie BirdDecatur$3K
- Mary SullivanGermantown$115K
- Len GetzMemphis$25K
- Judith CaldwellNashville$18K
- Mara HutchingsNashville$14K
- Reena BhaktaMurfreesboro$12K
- Ryan HartmanNashville$11K
- Martha LemonsBrentwood$11K
- Abigail EubankHendersonville$9K
- Corey ClelandSevierville$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.